一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-115 号 一心堂药业集团股份有限公司(以下简称"公司")于2025年5月21日召开2024年年度股东会， 审议通过《关于使用部分暂时闲置自有资金进行现金管理的议案》，同意公司及全资子公司使 用额度不超过人民币25亿元的闲置自有资金进行现金管理（包括但不限于购买一年期以内的固 定收益型或保本浮动收益型理财产品、大额存单、定期存款、通知存款、协定存款等），相关 额度在投资期限内任一时点的现金管理金额(含前述投资的收益进行再投资的相关金额)不超过 25亿元人民币。在上述额度内，资金可以滚动使用，在额度范围内授权董事长具体办理实施相 关事项。 一、使用部分暂时闲置自有资金进行现金管理情况 （一）本次进行现金管理基本情况 近日，公司与华夏银行股份有限公司昆明红塔支行签订了《华夏银行人民币单位结构性存 款业务协议》，本次进行现金管理基本情况如下： 一心堂药业集团股份有限公司 关于使用部分暂时闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 | 签约银行 | ...

Core Viewpoint - In October, the wholesale sales of passenger vehicles reached 2.93 million units, showing a year-on-year increase of 7% and a month-on-month increase of 4%, with retail sales estimated at 2.34 million units, up 3% year-on-year and 6% month-on-month. The effects of trade-in programs remain significant, and exports continue to grow, with October wholesale sales reaching a historical high for the month [1][2]. Group 1: Sales Performance - October wholesale sales of passenger vehicles were 2.93 million units, with a year-on-year increase of 7% and a month-on-month increase of 4%. Retail sales are estimated at 2.34 million units, with a year-on-year increase of 3% and a month-on-month increase of 6% [2]. - The penetration rate of electric vehicles (EVs) reached 55% in October, with wholesale sales of 1.62 million units, reflecting a year-on-year increase of 18% and a month-on-month increase of 8% [2]. - The wholesale sales of domestic car manufacturers reached 2.14 million units in October, with a year-on-year increase of 12% and a month-on-month increase of 8%, accounting for 73.1% of total sales [2]. Group 2: Inventory and Pricing - In October, exports totaled 570,000 units, representing a year-on-year increase of 23% and a month-on-month increase of 3%, leading to an increase in channel inventory of approximately 30,000 units [3]. - The industry discount rate in late October slightly increased, with an overall discount rate of 9.6%, up 0.1 percentage points month-on-month [2]. Group 3: Yearly Outlook - For Q4, retail sales are expected to reach 7.73 million units, with a year-on-year increase of 6%, while wholesale sales are projected at 8.67 million units, showing a year-on-year decrease of 1%. The total retail sales for the year are expected to be 24.23 million units, up 6.7% year-on-year, and wholesale sales at 29.61 million units, up 8.6% year-on-year [4]. Group 4: Investment Recommendations - As the year ends, various brands are gradually implementing policies to phase out purchase tax incentives, with expectations that Q4 sales will be less impacted than previously anticipated. The sector is expected to see a recovery as the impact of policy changes diminishes [5]. - Recommended stocks for investment include Geely Automobile and BYD, with a focus on Geely's valuation being in single digits for the coming year. Additionally, JAC Motors is highlighted for its strong product cycle and favorable pricing after recent adjustments [5].

Company Overview - Yunnan Yixintang Pharmaceutical Group Co., Ltd. is located in Kunming, Yunnan Province, and was established on November 8, 2000. The company was listed on July 2, 2014. Its main business involves retail and wholesale of pharmaceuticals, with revenue composition as follows: Western and Chinese medicines 75.03%, others 9.86%, traditional Chinese medicine 8.56%, and medical devices and disinfectants 6.55% [1][2]. Stock Performance - As of November 12, Yixintang's stock price increased by 2.02%, reaching 14.14 CNY per share, with a market capitalization of 8.28 billion CNY. The stock has risen 12.85% year-to-date, with a 5.52% increase over the last five trading days [1]. - The stock has appeared on the "Dragon and Tiger List" twice this year, with the most recent occurrence on May 23, where it recorded a net buy of -4.0951 million CNY [1]. Financial Performance - For the period from January to September 2025, Yixintang reported a revenue of 13.001 billion CNY, a year-on-year decrease of 4.33%, and a net profit attributable to shareholders of 269 million CNY, down 8.17% year-on-year [2][3]. Shareholder Information - As of September 30, 2025, Yixintang had 37,500 shareholders, an increase of 10.53% from the previous period. The average number of circulating shares per shareholder decreased by 9.53% to 10,596 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 22.3144 million shares, an increase of 3.74 million shares from the previous period. Several new institutional shareholders have entered the top ten list [3]. Dividend Distribution - Since its A-share listing, Yixintang has distributed a total of 2.023 billion CNY in dividends, with 764 million CNY distributed over the past three years [3].

Investment Rating - The report maintains an "Outperform" rating for the company [6]. Core Views - The company is a leading chain pharmacy in China, with a strong market presence in Central South, East China, and South China regions. It is expected to enhance its industry position through refined operations and the development of a new retail system, maintaining steady growth in revenue and profit [4][34]. - The company has shown slight revenue growth and strong profit growth in the first three quarters of 2025, with total revenue reaching 17.286 billion yuan, a year-on-year increase of 0.4%, and net profit attributable to shareholders of 1.225 billion yuan, up 10.3% year-on-year [1][9]. Summary by Sections Financial Performance - In Q3 2025, the company achieved revenue of 5.564 billion yuan, a 2.0% year-on-year increase, and net profit of 345 million yuan, up 10.1% year-on-year. The company is experiencing a marginal improvement trend in both revenue and profit due to the clearing of closed stores and initial alleviation of industry competition pressure [1][9]. - The company’s gross margin for the first three quarters of 2025 was 40.4%, with a net margin of 7.6%. The retail business achieved a gross margin of 42.0%, while the franchise and distribution business had a gross margin of 10.9% [2][15]. Operational Efficiency - The company maintains stable expense ratios, with a sales expense ratio of 25.0%, a management expense ratio of 4.7%, and a financial expense ratio of 0.7%. This stability is attributed to the company's strong operational capabilities [2][15]. - The company has been focusing on high-margin non-pharmaceutical products, which are expected to continue increasing their revenue share, thereby enhancing overall gross margin [2][15]. Market Position and Strategy - The company is transitioning from a focus on scale to quality and efficiency in response to increasing demand driven by aging populations and healthcare spending. The company has established a "fleet-type" store network to enhance operational efficiency and customer loyalty [3][34]. - The company has a total of 14,666 stores as of Q3 2025, with a slight decrease in total store count compared to the end of 2024. The company is adjusting its store expansion strategy in response to industry trends [29][87]. Future Projections - Revenue projections for 2025-2027 are 24.546 billion yuan, 27.292 billion yuan, and 30.444 billion yuan, with year-on-year growth rates of 2.0%, 11.2%, and 11.5% respectively. Net profit projections for the same period are 1.725 billion yuan, 2.007 billion yuan, and 2.316 billion yuan, with growth rates of 12.8%, 16.4%, and 15.4% respectively [4][5].

一心为民 全心服务 一心堂药业集团股份有限公司(以下简称"公司")于2025年5月21日召开2024年年度股东会， 审议通过《关于使用部分暂时闲置自有资金进行现金管理的议案》，同意公司及全资子公司使 用额度不超过人民币25亿元的闲置自有资金进行现金管理（包括但不限于购买一年期以内的固 定收益型或保本浮动收益型理财产品、大额存单、定期存款、通知存款、协定存款等），相关 额度在投资期限内任一时点的现金管理金额(含前述投资的收益进行再投资的相关金额)不超过 25亿元人民币。在上述额度内，资金可以滚动使用，在额度范围内授权董事长具体办理实施相 关事项。 一、使用部分暂时闲置自有资金进行现金管理情况 （一）本次进行现金管理基本情况 近日，公司与华夏银行股份有限公司昆明红塔支行签订了《华夏银行人民币单位结构性存 款业务协议》，本次进行现金管理基本情况如下： | 签约银行 | 产品名称 | 认购金额 | 收益类型 | 合同起始日 | 合同到期日 | 产品预期收 | | --- | --- | --- | --- | --- | --- | --- | | 名称 | | （万元） | | | | 益率（年） | | 华夏银行 ...

Company Overview - Yunnan Yixintang Pharmaceutical Group Co., Ltd. is located in Kunming, Yunnan Province, and was established on November 8, 2000. The company was listed on July 2, 2014. Its main business involves retail and wholesale of pharmaceuticals, with revenue composition as follows: Western and Chinese medicines 75.03%, others 9.86%, traditional Chinese medicine 8.56%, and medical devices and sanitary products 6.55% [1]. Stock Performance - As of November 10, Yixintang's stock price increased by 2.14%, reaching 13.83 CNY per share, with a trading volume of 1.04 billion CNY and a turnover rate of 1.92%. The total market capitalization is 80.99 billion CNY [1]. - Year-to-date, Yixintang's stock price has risen by 10.38%, with a 3.44% increase over the last five trading days, a 0.66% increase over the last 20 days, and a 6.01% decrease over the last 60 days [1]. Financial Performance - For the period from January to September 2025, Yixintang reported operating revenue of 13.001 billion CNY, a year-on-year decrease of 4.33%, and a net profit attributable to shareholders of 269 million CNY, down 8.17% year-on-year [2]. Shareholder Information - As of September 30, 2025, Yixintang had 37,500 shareholders, an increase of 10.53% from the previous period, with an average of 10,596 shares per shareholder, a decrease of 9.53% [2]. - The company has distributed a total of 2.023 billion CNY in dividends since its A-share listing, with 764 million CNY distributed in the last three years [3]. Institutional Holdings - As of September 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited as the third-largest shareholder with 22.3144 million shares, an increase of 3.74 million shares from the previous period. New institutional shareholders include several funds, such as Xingquan Trend Investment Mixed Fund and Rongtong Health Industry Flexible Allocation Mixed Fund [3].

Core Viewpoint - Yunnan's "Medicine King" Ruan Hongxian is in the spotlight following Yixin Hall's announcement of a share transfer to his daughters, amidst the company's ongoing performance decline and strategic transformation efforts [1][10]. Company Overview - Yixin Hall, founded by Ruan Hongxian, has grown to operate 11,372 pharmacies, establishing itself as a leading player in the southwestern Chinese pharmaceutical retail market [1][9]. - The company reported a revenue decline of 4.33% year-on-year to 13 billion yuan and a net profit drop of 8.17% to 269 million yuan for the first three quarters of 2025 [1]. Historical Background - Ruan Hongxian began his career in the pharmaceutical industry at the age of 14, eventually founding Yixin Hall in 2006 after years of building a reputation for quality [3][4]. - The company went public in 2014, marking a significant milestone in its expansion journey, with revenues reaching 17.43 billion yuan and net profits hitting 1.01 billion yuan by 2022 [4]. Strategic Challenges and Responses - The company has faced challenges such as declining gross margins due to policy changes and market competition, prompting Ruan to initiate a strategic transformation [7][8]. - A dual-track transformation strategy has been proposed, with plans to convert 70% of stores to multi-category health stores and 30% to professional pharmacies, enhancing the medical attributes of nearly one-third of the stores [8][9]. Family Succession and Future Outlook - Ruan Hongxian is transferring shares to his daughters as part of a family wealth succession plan, with the total value of the shares amounting to approximately 157 million yuan [1][10]. - The involvement of the next generation, particularly Ruan Aixiang as vice president, is seen as crucial for the company's innovative development amid ongoing transformation efforts [2][11].

Core Viewpoint - Yixin Tang Pharmaceutical Group Co., Ltd. announced a share transfer plan by its controlling shareholder and chairman, Ruan Hongxian, to his daughters, which will not affect the company's control or governance structure [1][4]. Group 1: Share Transfer Details - Ruan Hongxian plans to transfer up to 5.856 million shares (1% of total share capital) to each of his daughters, Ruan Shengxiang and Ruan Aixiang, through block trading within three months after the announcement [1][4]. - The share transfer is characterized as a family internal transfer, and Ruan Hongxian will sign a "consensus action agreement" with his daughters post-transfer [1]. Group 2: Company Background - As of November 6, Yixin Tang's total market value was 7.865 billion yuan, making the shares transferred to Ruan Hongxian's daughters worth over 78 million yuan [4]. - Yixin Tang was established on November 8, 2000, and as of September 30, 2025, it operates 11,230 direct chain stores, serving 210 million customers annually across 10 provinces and municipalities in China [4]. Group 3: Personal Background of Shareholders - Ruan Hongxian, aged 59, held 31.74% of Yixin Tang's shares before the transfer [4]. - Ruan Shengxiang serves as the vice chairman of Shengai Traditional Chinese Medicine Group, while Ruan Aixiang was appointed as vice president of Yixin Tang in July this year [6][8].

Core Viewpoint - The article discusses the internal share transfer of Yuantong's shares by Mr. Huan Hongxian to his daughters, the company's expansion into non-pharmaceutical sectors, and its overall performance in the retail pharmacy market. Group 1: Share Transfer and Management Changes - Mr. Huan Hongxian will transfer shares valued at approximately 157 million CNY to his daughters, maintaining control through a concerted action agreement, ensuring no change in company governance [3]. - Mr. Huan has held 182 million shares, representing 31.74% of the total share capital of Yuantong as of the announcement date [3]. Group 2: Company Overview and Expansion - Yuantong, established in November 2000, operates 11,230 retail stores across 10 provinces and municipalities, serving 210 million customers annually [3]. - The company plans to develop a new non-pharmaceutical business segment in 2025, focusing on health food, medical devices, and a broad health category, with significant contributions expected from beauty and personal care products [5]. Group 3: Financial Performance and Market Data - As of November 7, Yuantong's stock price was 13.54 CNY, with a total market capitalization of 7.929 billion CNY [5][7]. - The company reported a high double-digit growth in its non-pharmaceutical sales for the first three quarters of 2025, with 805 stores upgraded [5].

Investment Rating - The report maintains a "Market Weight" rating for the pharmaceutical and biotechnology industry, indicating that the industry is expected to perform within ±10% of the market index over the next six months [3][29]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, declining by 0.61% from October 24 to November 6, 2025, which is approximately 2.50 percentage points lower than the index [10][23]. - Most sub-sectors within the industry recorded negative returns during the same period, with the vaccine and pharmaceutical distribution sectors showing the highest gains of 2.87% and 2.33%, respectively, while offline pharmacies and medical research outsourcing experienced declines of 3.95% and 3.11% [11][12]. - Approximately 57% of stocks in the industry recorded positive returns, with notable performers including Hezhong China, which saw a weekly increase of 115.96% [15][12]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry lagged behind the CSI 300 index, with a decline of 0.61% from October 24 to November 6, 2025 [10]. - Most sub-sectors recorded negative returns, with vaccines and pharmaceutical distribution leading in gains [11]. - About 57% of stocks in the industry had positive returns, with significant fluctuations among individual stocks [15]. 2. Industry News - The 11th batch of national drug centralized procurement results was announced, involving 55 varieties and 445 companies, with a selection rate of 57% [21]. - The new procurement rules emphasize clinical stability, quality assurance, and higher standards for bidding companies [21]. 3. Company Announcements - Yekang Pharmaceutical announced that its subsidiary received approval for clinical trials of YKYY013 injection for chronic hepatitis B treatment [22]. 4. Industry Outlook - The report suggests focusing on investment opportunities in innovative drugs and sectors with expected business development catalysts, including medical devices and traditional Chinese medicine [25]. - Key companies to watch include Mindray Medical, Yifeng Pharmacy, and Aier Eye Hospital, among others [26].